91 related articles for article (PubMed ID: 14518214)
1. [CD95 resistance and Fas ligand synthesis as mechanism of defense by immunocompetent cells in pancreatic tumors].
Ungefroren H; Voss M; Henne-Bruns D; Kremer B; Kalthoff H
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):63-7. PubMed ID: 14518214
[TBL] [Abstract][Full Text] [Related]
2. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
[TBL] [Abstract][Full Text] [Related]
3. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
Elnemr A; Ohta T; Yachie A; Kayahara M; Kitagawa H; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
Int J Oncol; 2001 Jan; 18(1):33-9. PubMed ID: 11115536
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
[TBL] [Abstract][Full Text] [Related]
5. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
6. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
[TBL] [Abstract][Full Text] [Related]
7. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
[TBL] [Abstract][Full Text] [Related]
8. Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape.
Bernstorff WV; Glickman JN; Odze RD; Farraye FA; Joo HG; Goedegebuure PS; Eberlein TJ
Cancer; 2002 May; 94(10):2552-60. PubMed ID: 12173320
[TBL] [Abstract][Full Text] [Related]
9. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma.
Bellone G; Smirne C; Carbone A; Mareschi K; Dughera L; Farina EC; Alabiso O; Valente G; Emanuelli G; Rodeck U
Clin Cancer Res; 2000 Jun; 6(6):2448-55. PubMed ID: 10873098
[TBL] [Abstract][Full Text] [Related]
10. The Fas/Fas ligand system and cancer: immune privilege and apoptosis.
Abrahams VM; Kamsteeg M; Mor G
Mol Biotechnol; 2003 Sep; 25(1):19-30. PubMed ID: 13679631
[TBL] [Abstract][Full Text] [Related]
11. Fas/Fas ligand interactions are involved in ultraviolet-B-induced human lymphocyte apoptosis.
Caricchio R; Reap EA; Cohen PL
J Immunol; 1998 Jul; 161(1):241-51. PubMed ID: 9647230
[TBL] [Abstract][Full Text] [Related]
12. Immunological escape mechanisms in pancreatic carcinoma.
Ungefroren H; Voss M; Bernstorff WV; Schmid A; Kremer B; Kalthoff H
Ann N Y Acad Sci; 1999 Jun; 880():243-51. PubMed ID: 10415870
[TBL] [Abstract][Full Text] [Related]
13. CD95/CD95 ligand-mediated counterattack does not block T cell cytotoxicity.
Jekle A; Obst R; Lang F; Rammensee HG; Gulbins E
Biochem Biophys Res Commun; 2000 Jun; 272(2):395-9. PubMed ID: 10833425
[TBL] [Abstract][Full Text] [Related]
14. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications.
Strand S; Galle PR
Mol Med Today; 1998 Feb; 4(2):63-8. PubMed ID: 9547792
[TBL] [Abstract][Full Text] [Related]
15. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
[TBL] [Abstract][Full Text] [Related]
16. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
17. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
Gastman BR; Atarshi Y; Reichert TE; Saito T; Balkir L; Rabinowich H; Whiteside TL
Cancer Res; 1999 Oct; 59(20):5356-64. PubMed ID: 10537320
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression.
Mishima K; Nariai Y; Yoshimura Y
Int J Cancer; 2003 Jul; 105(5):593-600. PubMed ID: 12740905
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction.
Riffkin CD; Gray AZ; Hawkins CJ; Chow CW; Ashley DM
Neuro Oncol; 2001 Oct; 3(4):229-40. PubMed ID: 11584892
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Fas ligand does not confer immune privilege to a pancreatic beta tumor cell line (betaTC-3).
Okamoto S; Takamizawa S; Bishop W; Wen J; Kimura K; Sandler A
J Surg Res; 1999 Jun; 84(1):77-81. PubMed ID: 10334893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]